Stéphane Bancel, Moderna CEO (JPM20/Jeff Rumans)

With mR­NA proof of con­cept on dis­play in Covid-19, Mod­er­na plots HIV vac­cine moon­shot as part of pipeline ex­pan­sion

Mod­er­na’s march from ear­ly her­ald of mR­NA to sav­ior in the fight against Covid-19 has been a sight to be­hold as bet­ter-fund­ed com­peti­tors in the race for a vac­cine have fall­en by the way­side. Now, with its proof of con­cept val­i­dat­ed, Mod­er­na is adding to its ag­gres­sive R&D plan and look­ing to break ground along the way.

With an FDA emer­gency use au­tho­riza­tion for its mR­NA-based Covid-19 vac­cine show­ing promise for its once-un­like­ly mech­a­nism of ac­tion, Mod­er­na is ex­pand­ing its ever-grow­ing pipeline, which now in­cludes two long-shot tries at HIV, the com­pa­ny said Mon­day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.